Abstract: Processes for the preparation of 1,3-oxathiolane nucleosides are provided that include efficient methods for the preparation of the 1,3-oxathiolane ring and subsequent condensation of the 1,3-oxathiolane with a pyrimidine or purine base. Using the processes described herein, the compounds can be provided as isolated enantiomers.
Type:
Grant
Filed:
May 15, 2000
Date of Patent:
February 11, 2003
Assignees:
Emory University, Triangle Pharmaceuticals, Inc.
Inventors:
George R. Painter, Dennis C. Liotta, Merrick R. Almond, Darryl G. Cleary, Josè D. Soria, Marcos Sznaidman
Abstract: A method and composition for the treatment of HIV and HBV infections in humans and other host animals is disclosed that includes the administration of an effective amount of a [5-carboxamido or 5-fluoro]-2′,3′-dideoxy-2′,3′-didehydro-pyrimidine nucleoside or a [5-carboxamido or 5-fluoro]-3′-modified-pyrimidine nucleoside, or a mixture or a pharmaceutically acceptable derivative thereof, including a 5′ or N4 alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.
Abstract: Disclosed are compositions and methods to generate a protective or therapeutic immune response to neoplastic cells (e.g., tumor cells) which, in nature, lack a CoCAM surface molecule essential for a cytotoxic immune response. GPI-anchored CoCAM molecules are incorporated (by GPI-protein transfer) into neoplastic cells, neoplastic cell membrane preparations or neoplastic membrane vesicle preparations and formulated in immunogenic compositions. A specifically exemplified GPI-CoCAM is a B7.1/CD16B fusion protein, having the GPI anchor domain from the CD16B molecule.
Abstract: Controlled cessation of heart beat during coronary bypass surgery and other cardiac surgeries on a beating heart improves surgical technique, and is achieved typically by electrical stimulation of the vagus nerve and administration of a combination of drugs.
Abstract: A water soluble delivery system for nucleic acids to cells having androgen receptors, preferably prostate cells, is provided comprising a steroid moiety capable of binding to said receptors, said steroid moiety being covalently linked to a polycationic material. This molecule may be complexed with therapeutic or diagnostic nucleic acids. Methods of diagnosis and therapy using these compositions are also provided, including gene therapy treatments for prostate cancer.
Abstract: The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, incluidng angiongenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.
Type:
Grant
Filed:
December 26, 2000
Date of Patent:
October 8, 2002
Assignees:
The University of Georgia Research Foundation, Inc., Emory University
Inventors:
J. Phillip Bowen, Thomas Phillip Robinson, Tedman Ehlers, David Goldsmith, Jack Arbiser
Abstract: A recombinant RNA-dependent RNA polymerase of hepatitis C virus (r-HCV-RDRP) coding DNA was cloned and expressed yielding active enzyme in vitro. The r-HCV-RDRP can include up to 20 added amino acids and up to nine deleted or substituted amino acids at the NH2-terminus of the encoded amino acid sequence. The invention provides method to solubilize r-HCV-RDRP from a host cell lysate and purified r-HCV-RDRP. Methods for screening for inhibitors of r-HCV-RDRP in vitro, for making stably transfected mammalian cells expressing r-HCV-RDRP and for in vivo testing of r-HCV-RDRP inhibitors in vivo are disclosed. The invention provides antibodies to r-HCV-RDRP and methods for detecting antibodies to HCV-RDRP in serum of human patients.
Abstract: A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (−)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.
Type:
Application
Filed:
February 11, 2002
Publication date:
October 3, 2002
Applicant:
Emory University
Inventors:
Dennis C. Liotta, Raymond F. Schinazi, Woo-Baeg Choi
Abstract: Compounds and pharmaceutical compositions active against hepatitis B virus are provided, as is a method for the treatment of hepatitis B virus infection in humans and other host animals is provided comprising administering an effective amount of a &bgr;-L-(2′or 3′-azido)-2′,3′-dideoxy-5-fluorocytosine of the formula
wherein R is H, acyl, monophosphate, diphosphate, or triphosphate, or a stabilized phosphate derivative (to form a stabilized nucleotide prodrug), and R′is H, acyl, or alkyl.
Type:
Grant
Filed:
November 5, 1999
Date of Patent:
October 1, 2002
Assignees:
Emory University, Centre National de la Recherche Scientifique, UAB Research Foundation
Inventors:
Gilles Gosselin, Jean-Louis Imbach, Jean-Pierre Sommadossi, Raymond F. Schinazi
Abstract: The invention relates to a modified B-domainless form of porcine factor VIII, to a DNA encoding the same, and to the use thereof for treatment of hemophilia.
Abstract: The present invention is directed to isolated nucleic acid molecules that encode LIM mineralization protein, or LMP. The invention further provides vectors comprising nucleotide sequences that encode LMP, as well as host cells comprising those vectors. Moreover, the present invention relates to methods of inducing bone formation by transfecting osteogenic precursor cells with an isolated nucleic acid molecule comprising a nucleotide sequence encoding LIM mineralization protein. The transfection may occur ex vivo or in vivo by direct injection of virus or naked plasmid DNA. In a particular embodiment, the invention provides a method of fusing a spine by transfecting osteogenic precursor cells with an isolated nucleic acid molecule having a nucleotide sequence encoding LIM mineralization protein, admixing the transfected a osteogenic precursor cells with a matrix and contacting the matrix with the spine.
Abstract: The invention relates to an a process for making a 4-substituted pyrrole-2-carbaldehyde compound comprising reacting:
a. a pyrrole-2-carbaldehyde compound; and
b. an alkylating agent;
c. in the presence of at least one catalyst; to form a 4-alkyl substituted pyrrole-2-carbaldehyde compound.
Abstract: A method for synthesizing porphyrin compounds includes the step of removing one or more substituent groups from a substituted porphyrin compound. Preferably, the removal step involves acid cleavage and the substituent group is an acid cleavable substituent such as a t-butyl group. Another aspect involves a method which produces porphyrin compounds from substituted pyrrole compounds, where the substituent on the pyrrole compound selected so as to aid in the porphyrin ring formation, which substituent can be subsequently removed. In this regard, the method comprises (i) reacting the substituted pyrrole compound so as to provide a substituted porphyrin compound containing the substituent(s) followed by (ii) removal of the substituents from the substituted porphyrin compound.
Abstract: Controlled cessation of heart beat during coronary bypass surgery and other cardiac surgeries on a beating heart improves surgical technique, and is achieved typically by electrical stimulation of the vagus nerve and administration of a combination of drugs.
Abstract: An apparatus and method for transcranial magnetic brain stimulation. The apparatus allows transcranial stimulation at higher power efficiency and lower heat generation than prior available magnetic stimulator coils without an iron core. Use of the apparatus allows an improved method for active localization of language function. The device can also be used in rapid rate transcranial magnetic stimulation for the treatment of depression.
Abstract: A process for detecting mutations in the gene responsible for glactosemia, galatose-1-phosphate uridyl transferase (GALT), is described. In one embodiment, the process can be used to detect over 85% of the mutations known to cause galactosemia in the United States population by using six different oligonucleotide probes, which span single-nucleotide Missense or nonsense mutations in the GALT gene. Hybridization conditions which can distinguish a single nucleotide mismatch are used to detect both the presence and zygosity of mutations in the GALT gene to aid in genetic counselling. A kit for use in detecting mutations in the GALT gene is also disclosed.
Type:
Grant
Filed:
March 26, 2001
Date of Patent:
July 16, 2002
Assignee:
Emory University
Inventors:
Louis J. Elsas, II, Kasinathan Muralidharan
Abstract: A topical skin protectant formulation containing a barrier cream and a active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWAs). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.
Type:
Grant
Filed:
June 1, 2001
Date of Patent:
June 25, 2002
Assignees:
The United States of America as represented by the Secretary
of the Army, Nanoscale Materials, Inc., Emory University
Inventors:
Stephen T. Hobson, Ernest H. Braue, Erich K. Lehnert, Kenneth J. Klabunde, Shawn Decker, Craig L. Hill, Jeffrey Rhule, Eric Boring, Olga Koper
Abstract: Compounds and pharmaceutical compositions active against HIV are provided, as is a method for the treatment of HIV infection in humans and other host animals is provided comprising administering an effective amount of a &bgr;-L-(2′ or 3′-azido)-2′,3′-dideoxy-5-fluorocytosine of the formula
wherein R is H, acyl, monophosphate, diphosphate, or triphosphate, or a stabilized phosphate derivative (to form a stabilized nucleotide prodrug), and R′ is H, acyl, or alkyl.
Type:
Grant
Filed:
November 5, 1999
Date of Patent:
June 18, 2002
Assignees:
Emory University, Centre National de la Recherche Scientifique, The UAB Research Foundation
Inventors:
Gilles Gosselin, Jean-Louis Imbach, Jean-Pierre Sommadossi, Raymond F. Schinazi
Abstract: The present invention is based on the discovery of meningococcal isolates having genetic markers of a particular serogroup but expressing a capsular polysaccharide of a different serogroup. These isolates and prototype serogroup A, B, C, Y and W-135 strains were used to define the capsular biosynthetic operon of the major meningococcal serogroups and to show that capsule switching occurs as a result of allelic exchange of, for example, the polysialyl-transferase gene. Findings of capsule switching in vivo indicate that closely related virulent meningococcal clones may not be recognized by traditional serogroup-based surveillance and can escape vaccine-induced or natural protective immunity by capsule switching.